Fifth Third Bancorp’s CytomX Therapeutics CTMX Stock Holding History

Fifth Third Bancorp’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,490	Closed	-$12K	–	2149
2019 Q4	$12K	Hold	1,490	–	–	﹤0.01%	1794
2019 Q3	$11K	Hold	1,490	–	–	﹤0.01%	1772
2019 Q2	$17K	Hold	1,490	–	–	﹤0.01%	1677
2019 Q1	$16K	Hold	1,490	–	–	﹤0.01%	1643
2018 Q4	$22K	Hold	1,490	–	–	﹤0.01%	1531
2018 Q3	$28K	Hold	1,490	–	–	﹤0.01%	1506
2018 Q2	$34K	Hold	1,490	–	–	﹤0.01%	1445
2018 Q1	$42K	Hold	1,490	–	–	﹤0.01%	1394
2017 Q4	$31K	Hold	1,490	–	–	﹤0.01%	1444
2017 Q3	$27K	Hold	1,490	–	–	﹤0.01%	1498
2017 Q2	$23K	Hold	1,490	–	–	﹤0.01%	1512
2017 Q1	$26K	Hold	1,490	–	–	﹤0.01%	1496
2016 Q4	$16K	Hold	1,490	–	–	﹤0.01%	1663
2016 Q3	$23K	Hold	1,490	–	–	﹤0.01%	1571
2016 Q2	$15K	Buy	1,490 +750	+101%	+$8.55K	﹤0.01%	1662
2016 Q1	$10K	Hold	740	–	–	﹤0.01%	1851
2015 Q4	$15K	Buy	+740	New	+$11.7K	﹤0.01%	1787

Other funds holding CTMX

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fifth Third Bancorp's CTMX Position: Q1 2020 in Review

Fifth Third Bancorp sold out of CytomX Therapeutics (CTMX) in Q1 2020, closing a stake of 1,490 shares — an estimated $12K sold.

Fifth Third Bancorp first reported a position in CTMX in Q4 2015 and held it in 17 quarters. The position peaked at $42K in Q1 2018. 117 funds tracked by Wall St. Rank hold CTMX as of Q1 2020.

Fifth Third Bancorp reported no remaining CytomX Therapeutics position as of Q1 2020 after selling out during the quarter.
Fifth Third Bancorp sold 1,490 CytomX Therapeutics shares in Q1 2020, an estimated $12K.
Fifth Third Bancorp first reported a position in CytomX Therapeutics in Q4 2015 and held it in 17 quarters.
Fifth Third Bancorp's CytomX Therapeutics position peaked at $42K in Q1 2018.
117 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2020.

Based on Fifth Third Bancorp's 13F filing for Q1 2020, filed 5 May 2020.